Stay updated with breaking news from Eduardo Sim. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
A coronavirus vaccine developed by China's Sinovac Biotech was just 50.4% effective at preventing symptomatic infections in a Brazilian trial, researchers said on Tuesday, barely enough for regulatory approval and well below the rate announced last week.
Brazil CoronaVac producer files for emergency use Outbreak of the coronavirus disease (COVID-19) in Brazil SAO PAULO (Reuters) – The Brazilian production partner for a coronavirus vaccine developed by China’s Sinovac Biotech filed on Friday for emergency use authorization with health regulator Anvisa, the day after announcing results from a late-stage trial. The Chinese vaccine is the first with an emergency use request filed in Brazil, where more than 200,000 have died of COVID-19 – the worst death toll outside the United States. Anvisa will evaluate the request and reach a conclus...
Doses of a COVID-19 vaccine made by China's Sinovac Biotech are rolling off a Brazilian production line, drawing interest around the country and across Latin America from governments struggling to procure costlier vaccines.
By Eduardo Simões SAO PAULO, Jan 7 (Reuters) - A COVID-19 vaccine developed by China's Sinovac Biotech was 78% effective in a late-stage Brazilian trial and entirely prevented severe cases, researchers said on Thursday, boosting Chinese efforts to catch up with Western vaccine makers. The announced efficacy, closely watched by developing countries counting on the vaccine to begin mass inoculations, was weaker than preliminary findings from Turkish researchers and lacked detailed data provided on U.S. and European vaccines. The director of Brazilian biomedical center Butantan, Sinovac's resea...
UPDATE 5-Sinovac vaccine 78% effective in Brazil trial, experts call for more details Reuters 1/7/2021 By Eduardo Simões SAO PAULO, Jan 7 (Reuters) - A coronavirus vaccine developed by China's Sinovac Biotech was 78% effective in a late-stage Brazilian trial with no severe COVID-19 cases, researchers said on Thursday, although a lack of data details stirred calls for more transparency. The trial results, closely watched by developing countries counting on the vaccine to begin mass inoculations to help end a raging pandemic, was below preliminary findings from Turkish researchers and lacked...